Melanotan II is also closely related to melanotan I a drug that is currently approved and marketed as afamelanotide (Scenesse) for the treatment of phototoxic reactions from erythropoietic protoporphyria, so current claims about the drug seem to have some validity
Prescribing decisions should be individualised, considering the patient's specific needs, comorbidities, and treatment goals
Implementation of quality by design (QbD) approach in development of QCT-SMEDDS with combination of AgNPs for diabetic foot ulcer management
[DOI] [PubMed] [Google Scholar] 328.Khorrami Chokami K., Khorrami Chokami A., Cammarata G., Piras G., Albertelli M., Gatto F., Vera L., Ferone D., Boschetti M
Mike Haney: When you talk about stopping the medications, what do you think about the concept of metabolic whiplash
10.1210/jc.2008-1641 100 PykeC.HellerR